UY26909A1 - PIRAZOL DERIVATIVES - Google Patents
PIRAZOL DERIVATIVESInfo
- Publication number
- UY26909A1 UY26909A1 UY26909A UY26909A UY26909A1 UY 26909 A1 UY26909 A1 UY 26909A1 UY 26909 A UY26909 A UY 26909A UY 26909 A UY26909 A UY 26909A UY 26909 A1 UY26909 A1 UY 26909A1
- Authority
- UY
- Uruguay
- Prior art keywords
- syndrome
- formula
- pirazol derivatives
- pirazol
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuesto de la fórmula (I); y composiciones farmacéuticas y métodos que comprenden compuestos de la fórmula (I) para tratar la fertilidad masculina y la motilidad espermática; diabetes mellitus; deterioro de la tolerancia a la glucosa; síndrome metabólico o síndrome X; síndrome de poliquistosis ovárica, adipogenesis y obesidad; miogenesis y fragilidad.Compound of the formula (I); and pharmaceutical compositions and methods comprising compounds of the formula (I) for treating male fertility and sperm motility; Mellitus diabetes; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovarian syndrome, adipogenesis and obesity; Myogenesis and fragility.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22941500P | 2000-08-31 | 2000-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26909A1 true UY26909A1 (en) | 2002-03-22 |
Family
ID=22861151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26909A UY26909A1 (en) | 2000-08-31 | 2001-08-27 | PIRAZOL DERIVATIVES |
Country Status (38)
Country | Link |
---|---|
EP (1) | EP1313710A1 (en) |
JP (1) | JP2004507526A (en) |
KR (1) | KR20030027093A (en) |
CN (1) | CN1518543A (en) |
AP (1) | AP2001002266A0 (en) |
AR (1) | AR035345A1 (en) |
AU (1) | AU2001280009A1 (en) |
BG (1) | BG107455A (en) |
BR (1) | BR0113574A (en) |
CA (1) | CA2420363A1 (en) |
CR (1) | CR6881A (en) |
CZ (1) | CZ2003468A3 (en) |
DO (1) | DOP2001000243A (en) |
DZ (1) | DZ3398A1 (en) |
EA (1) | EA200300205A1 (en) |
EC (1) | ECSP034480A (en) |
EE (1) | EE200300085A (en) |
GT (1) | GT200100179A (en) |
HN (1) | HN2001000192A (en) |
HR (1) | HRP20030140A2 (en) |
HU (1) | HUP0302669A3 (en) |
IL (1) | IL154016A0 (en) |
IS (1) | IS6687A (en) |
MA (1) | MA26946A1 (en) |
MX (1) | MXPA03001785A (en) |
NO (1) | NO20030958L (en) |
NZ (1) | NZ523656A (en) |
OA (1) | OA12368A (en) |
PA (1) | PA8528101A1 (en) |
PE (1) | PE20020470A1 (en) |
PL (1) | PL360742A1 (en) |
SK (1) | SK2002003A3 (en) |
SV (1) | SV2002000618A (en) |
TN (1) | TNSN01132A1 (en) |
UY (1) | UY26909A1 (en) |
WO (1) | WO2002018346A1 (en) |
YU (1) | YU14703A (en) |
ZA (1) | ZA200301064B (en) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (en) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CA2432303C (en) * | 2000-12-21 | 2010-04-13 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
IL161047A0 (en) * | 2001-09-27 | 2004-08-31 | Applied Research Systems | Pyrazole derivatives for increasing endogenous testosterone levels |
AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
CA2492673A1 (en) * | 2002-07-17 | 2004-01-22 | Pharmacia Italia S.P.A. | Heterobicyclic pyrazole derivatives as kinase inhibitors |
MXPA05003432A (en) * | 2002-10-09 | 2005-07-05 | Pfizer Prod Inc | Pyrazole compounds for treatment of neurodegenerative disorders. |
US7582630B2 (en) * | 2002-10-15 | 2009-09-01 | Smithkline Beecham Corporation | Pyradazine compounds as GSK-3 inhibitors |
EP1597234B1 (en) * | 2003-02-27 | 2008-10-08 | Smithkline Beecham Corporation | Novel compounds |
PT1626714E (en) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diaryl ureas for diseases mediated by pdgfr |
EP2511267A1 (en) * | 2003-06-05 | 2012-10-17 | Elan Pharmaceuticals Inc. | 3-((n-acylated aminoacyl)amino)pyrazoles as inhibitors of beta-amyloid peptide production useful for the treatment of alzheimer's disease |
JP4681548B2 (en) | 2003-07-22 | 2011-05-11 | アステックス・セラピューティクス・リミテッド | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase (CDK) and glycogen synthetase kinase-3 (GSK-3) modulators |
BR122016015715B8 (en) | 2003-07-23 | 2021-05-25 | Bayer Healthcare Llc | pharmaceutical compositions of 4[4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy)-pyridine-2-carboxylic acid methylamide |
CA2532231A1 (en) * | 2003-07-25 | 2005-02-03 | Pfizer Inc. | Aminopyrazole compounds and use as chk1 inhibitors |
CA2547283C (en) * | 2003-11-26 | 2010-11-09 | Pfizer Products Inc. | Aminopyrazole derivatives as gsk-3 inhibitors |
US7244757B2 (en) | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
JP2007533717A (en) * | 2004-04-21 | 2007-11-22 | アストラゼネカ アクチボラグ | Compound |
EP2295427A1 (en) | 2004-04-30 | 2011-03-16 | Bayer HealthCare, LLC | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
EP1781637A1 (en) * | 2004-06-29 | 2007-05-09 | Rigel Pharmaceuticals, Inc. | 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade |
US7491720B2 (en) | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
BRPI0517737A (en) | 2004-11-17 | 2008-10-21 | Miikana Therapeutics Inc | kinase inhibitors |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
AR054425A1 (en) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO. |
NZ561145A (en) | 2005-02-04 | 2011-02-25 | Astrazeneca Ab | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
EP1847531A4 (en) * | 2005-02-09 | 2009-04-22 | Takeda Pharmaceutical | Pyrazole compound |
KR101362621B1 (en) | 2005-02-16 | 2014-02-13 | 아스트라제네카 아베 | Chemical compouns |
WO2006123113A2 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
EP1741708A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP1928456B1 (en) | 2005-09-30 | 2015-04-22 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
AU2006307657B2 (en) | 2005-10-28 | 2010-10-28 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
JP2009513672A (en) | 2005-10-31 | 2009-04-02 | ブレインセルス,インコーポレイティド | GABA receptor-mediated regulation of neurogenesis |
US7820685B2 (en) | 2005-11-03 | 2010-10-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
CA2666794C (en) * | 2006-10-18 | 2017-12-12 | Periness Ltd. | Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
MX2009004140A (en) | 2006-10-21 | 2009-07-10 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors. |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
CA2676357A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
JP2010533729A (en) | 2007-07-17 | 2010-10-28 | プレキシコン,インコーポレーテッド | Compounds and methods for kinase regulation, and adaptations therefor |
WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
UA101166C2 (en) | 2007-09-21 | 2013-03-11 | Аррей Биофарма Инк. | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
WO2009130900A1 (en) * | 2008-04-24 | 2009-10-29 | 日本曹達株式会社 | Oxime derivative, intermediate compound, and plant disease control agent |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
MX2011008303A (en) | 2009-04-03 | 2011-11-29 | Plexxikon Inc | Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof. |
JP2013506691A (en) * | 2009-10-02 | 2013-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Pyrazole inhibitors of phosphatidylinositol 3-kinase |
PE20121327A1 (en) | 2009-11-06 | 2012-10-18 | Plexxikon Inc | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES, AND INDICATIONS THEREOF |
MX336726B (en) | 2010-09-27 | 2016-01-27 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors. |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
RS58455B1 (en) | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
SG11201601135QA (en) | 2013-08-16 | 2016-03-30 | Merck Patent Gmbh | 3-substituted cyclopentylamine derivatives |
CN106580986B (en) * | 2016-11-28 | 2017-09-15 | 王保亮 | A kind of pharmaceutical composition for treating teen bra |
BR112021011578A2 (en) | 2018-12-31 | 2021-08-31 | Biomea Fusion, Llc | IRREVERSIBLE GIRL-MLL INTERACTION INHIBITORS |
TW202043205A (en) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Inhibitors of menin-mll interaction |
BR112021012635A2 (en) * | 2019-01-31 | 2021-12-14 | Pfizer | 3-Carbonylamino-5-cyclopentyl-1fi-pyrazole compounds having inhibitory activity on cdk2 |
WO2022135442A1 (en) * | 2020-12-22 | 2022-06-30 | 上海拓界生物医药科技有限公司 | Cdk2 inhibitor and preparation method therefor |
CA3223223A1 (en) | 2021-06-28 | 2023-01-05 | Blueprint Medicines Corporation | Cdk2 inhibitors |
WO2023274397A1 (en) * | 2021-07-01 | 2023-01-05 | 上海拓界生物医药科技有限公司 | Cdk2 inhibitor, preparation method therefor and use thereof |
CA3229150A1 (en) | 2021-08-20 | 2023-02-23 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cance |
WO2023083201A1 (en) * | 2021-11-09 | 2023-05-19 | 上海拓界生物医药科技有限公司 | Aminopyrazole derivative, and preparation method therefor and use thereof |
WO2023092088A1 (en) * | 2021-11-19 | 2023-05-25 | Blueprint Medicines Corporation | Cdk2 inhibitors and methods of making and using same |
WO2023239629A1 (en) * | 2022-06-06 | 2023-12-14 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade cdk2 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2198999A (en) * | 1997-12-22 | 1999-07-12 | Bayer Corporation | Inhibition of raf kinase using substituted heterocyclic ureas |
KR100579792B1 (en) * | 1998-05-13 | 2006-05-12 | 동화약품공업주식회사 | Novel 2,5-pyridinedicarboxylic acid derivatives |
GB9811427D0 (en) * | 1998-05-29 | 1998-07-22 | Zeneca Ltd | Chemical compounds |
AU6314900A (en) * | 1999-07-26 | 2001-02-13 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
EA005373B1 (en) * | 1999-08-12 | 2005-02-24 | Фармация Италия С.П.А. | Amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
AP2002002530A0 (en) * | 1999-11-30 | 2002-06-30 | Pfizer Prod Inc | 2,4 diaminopyrimidine compounds useful as immunosuppressants. |
MXPA02010222A (en) * | 2000-04-18 | 2003-05-23 | Agouron Pharma | Pyrazoles for inhibiting protein kinase. |
-
2001
- 2001-08-24 JP JP2002523464A patent/JP2004507526A/en active Pending
- 2001-08-24 AP APAP/P/2001/002266A patent/AP2001002266A0/en unknown
- 2001-08-24 EE EEP200300085A patent/EE200300085A/en unknown
- 2001-08-24 EA EA200300205A patent/EA200300205A1/en unknown
- 2001-08-24 PL PL36074201A patent/PL360742A1/en not_active Application Discontinuation
- 2001-08-24 CZ CZ2003468A patent/CZ2003468A3/en unknown
- 2001-08-24 SK SK200-2003A patent/SK2002003A3/en not_active Application Discontinuation
- 2001-08-24 DZ DZ013398A patent/DZ3398A1/en active
- 2001-08-24 YU YU14703A patent/YU14703A/en unknown
- 2001-08-24 WO PCT/IB2001/001540 patent/WO2002018346A1/en not_active Application Discontinuation
- 2001-08-24 OA OA1200300050A patent/OA12368A/en unknown
- 2001-08-24 CN CNA018147615A patent/CN1518543A/en active Pending
- 2001-08-24 EP EP01958287A patent/EP1313710A1/en not_active Withdrawn
- 2001-08-24 CA CA002420363A patent/CA2420363A1/en not_active Abandoned
- 2001-08-24 AU AU2001280009A patent/AU2001280009A1/en not_active Abandoned
- 2001-08-24 HU HU0302669A patent/HUP0302669A3/en unknown
- 2001-08-24 IL IL15401601A patent/IL154016A0/en unknown
- 2001-08-24 KR KR10-2003-7002894A patent/KR20030027093A/en not_active Application Discontinuation
- 2001-08-24 NZ NZ523656A patent/NZ523656A/en unknown
- 2001-08-24 BR BR0113574-0A patent/BR0113574A/en not_active IP Right Cessation
- 2001-08-24 MX MXPA03001785A patent/MXPA03001785A/en not_active Application Discontinuation
- 2001-08-27 UY UY26909A patent/UY26909A1/en not_active Application Discontinuation
- 2001-08-28 HN HN2001000192A patent/HN2001000192A/en unknown
- 2001-08-29 PE PE2001000872A patent/PE20020470A1/en not_active Application Discontinuation
- 2001-08-29 AR ARP010104115A patent/AR035345A1/en unknown
- 2001-08-29 DO DO2001000243A patent/DOP2001000243A/en unknown
- 2001-08-30 SV SV2001000618A patent/SV2002000618A/en unknown
- 2001-08-30 GT GT200100179A patent/GT200100179A/en unknown
- 2001-08-30 TN TNTNSN01132A patent/TNSN01132A1/en unknown
- 2001-08-31 PA PA20018528101A patent/PA8528101A1/en unknown
-
2003
- 2003-01-13 BG BG107455A patent/BG107455A/en unknown
- 2003-01-15 CR CR6881A patent/CR6881A/en not_active Application Discontinuation
- 2003-01-16 IS IS6687A patent/IS6687A/en unknown
- 2003-02-07 ZA ZA200301064A patent/ZA200301064B/en unknown
- 2003-02-17 EC EC2003004480A patent/ECSP034480A/en unknown
- 2003-02-21 MA MA27050A patent/MA26946A1/en unknown
- 2003-02-26 HR HR20030140A patent/HRP20030140A2/en not_active Application Discontinuation
- 2003-02-28 NO NO20030958A patent/NO20030958L/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY26909A1 (en) | PIRAZOL DERIVATIVES | |
UY26862A1 (en) | IMIDAZOL DERIVATIVES | |
BR0206433A (en) | Compound, pharmaceutical composition, process for preparing a compound, and use of a compound | |
BR0314864A (en) | Organic compounds | |
CR8402A (en) | INDAZOL-O-GLUCOSIDS SUBSTITUTES | |
BR0309546A (en) | A compound, a pharmaceutical composition comprising the same, a process for its preparation and use and a method for the prophylactic or therapeutic treatment of type II diabetes. | |
NO20054787L (en) | Indene derivatives as pharmaceuticals | |
BRPI0113162B8 (en) | non-imidazole aryloxyalkylamine compounds and pharmaceutical composition comprising said compounds | |
ECSP034830A (en) | SUBSTITUTED DERIVATIVES OF CICLOHEXANO-1,4- DIAMINE | |
NO940595D0 (en) | Cyclic derivatives, drugs containing these compounds and process of their preparation | |
BR0213539A (en) | Compounds, process for preparing compounds, pharmaceutical compositions comprising a compound method for the treatment and / or prophylaxis of diseases that are associated with dpp iv and use of such compounds | |
BRPI0519106A2 (en) | compounds, their use, process for their manufacture, pharmaceutical compositions, method for the treatment and / or prophylaxis of diseases that are associated with dpp-iv | |
BR0108871A (en) | Compound, compound preparation process and pharmaceutical composition | |
PL1609785T3 (en) | C-glycoside derivatives and salts thereof | |
NO20034661L (en) | Nociceptin analogues | |
BR0215027A (en) | 6-Aminomorphinan derivatives, preparation process and its application | |
BR0317129A (en) | Substrate treatment to improve ink adhesion to substrates | |
BRPI0712889A8 (en) | compound, process for the preparation of a compound, intermediate compound, and, pharmaceutical composition. | |
CR9391A (en) | DERIVATIVES OF INDANIL-PIPERAZINAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
BR0212353A (en) | Compound, pharmaceutical composition, and use of a compound | |
DK1408966T3 (en) | Synergistic pharmaceutical combinations for the prevention or treatment of diabetes | |
BR0213481A (en) | Probes | |
BR0101228A (en) | Ormoceres, process for its preparation, as well as application | |
BR9714066A (en) | Process for the preparation of thiazole derivatives. | |
BR0009453A (en) | Process for the preparation of a compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20141021 |